You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: OSSIUM HEALTH INC Topic: NHLBI
PROJECT SUMMARY Mesenchymal stem cells (MSC) are in clinical development for cardiovascular, neurologic, orthopedic, and other indications. Ossium is developing a novel source of MSC from vertebral bodies (vbMSC). Genetic modification of vbMSC using lentiviral vector (LV) has the potential to improve the therapeutic potential. Understanding how genetic modification might alter the vbMSC phenotype ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Navigation Sciences, Inc. Topic: 102
ABSTRACT The long-term goal of this project is to develop and commercialize a navigation system that can accurately determine margins in real-time during surgery for lung cancer. Surgery is currently the standard of care for early stage lung cancer. A critical challenge is to reliably identify small, early-stage tumors and resect them with sufficient margins (distance between the edge of tumor and ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ZEBRA BIOLOGICS INC Topic: 300
Project Summary/AbstractRelaxin is a heterodimeric 53 amino acid peptide hormone that induces cardiovascular compliance and reproductive tissue remodeling during pregnancy and parturition. In addition to reproductive organs, the relaxin receptor, RXFP1, is also expressed in the liver, heart, lung, kidney, bone and skin. This broad tissue localization has led to the recognition that relaxin is a pl ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: SERPLUS TECHNOLOGY LLC Topic: 200
PROJECT SUMMARY The number of people with diabetes worldwide is predicted to increase from 415 million in 2015 to 642 million in 2040. The health care costs of treating diabetes accounts for 12% of the global health expenditure of which Type 1 diabetes mellitus (T1DM) constitutes 10-15% of the disease burden (IDF World Atlas 2015). T1DM is an autoimmune disease triggered by genetic and/or environm ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Chesapeake Genomic Systems LLC Topic: 400
In vitro assembly of DNA fragments andgt;20 kb has recently identified as a critical technical challenge for writing synthetic genomes. Meeting this challenge will increase the efficiency of genome writing projects that depend on large synthetic DNAs, which are iteratively recombined to replace chromosome regions in a step-wise manner to partially or completely re-write bacterial or yeast chromoso ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's DiseaseSBC: WELLSIM BIOMEDICAL TECHNOLOGIES INC Topic: NIA
PROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: NIA
Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: XDemics Corporation Topic: 100
PROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infantsSBC: 149 MEDICAL INC Topic: 103
PROJECT SUMMARY/ABSTRACT Every year in the United States about 30% of the 60,000 infants born extremely premature (andlt;30 weeks gestational age and andlt;1000 g birth-weight [ELGA]) develop intraventricular hemorrhage (IVH). IVH is associated with high risk for cerebral palsy and significant intellectual disability, causing lifelong implications for affected children and their families and consi ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: FAUNA BIO INCORPORATED Topic: NHGRI
Project Summary/Abstract:Low-cost sequencing has ushered in a new era of drug discovery that can that utilize genomic information from hundreds of thousands of people. However, humans are a limited resource for identifying novel drug targets, and attempts at therapeutic development often rely on an already well-known set of genes and pathways. Greater potential for discovery exists if we broaden o ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health